

Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron) - Global Opportunities and Forecast 2014-2022

<https://marketpublishers.com/r/G2460A85F3EEN.html>

Date: January 2017

Pages: 70

Price: US\$ 5,540.00 (Single User License)

ID: G2460A85F3EEN

Abstracts

Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer.

The global Chemotherapy-induced Nausea and Vomiting market was valued at \$1,663 million in 2015, and is estimated to reach \$2, 659 million by 2022, registering a CAGR of 7.1% during the forecast period. At present, pharmaceutical companies are increasingly investing in the further discovery of CINV drugs through focused clinical research studies. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast, lung and bronchus cancer as most common along all the types in addition to existing number of cancer patients.

The global CINV market is segmented into patient pool type and geography. The patient pool type is segmented into namely Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC and Others. Among the segments, the Netupitant Palonosetron market is expected to witness the fastest growth, globally during the forecast period 2016-2022.

Based on geography, the global CINV market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share (nearly half) in the global chemotherapy-induced nausea and vomiting market in 2015 due to growth in demand for CINV drugs due to the rise in number of patients undergoing chemotherapy, introduction of novel delivery methods to improve patient compliance. However, Asian region is expected to grow at a fastest CAGR during the forecast period, owing to large

CINV patient pool and huge demand for the Netupitant–Palonosetron from these patients. Netupitant - Palonosetron is one of the first forms of fixed dose combination, which is approved for treating chemotherapy-induced nausea and vomiting that is likely to drive this market in the near future.

KEY BENEFITS

The study provides in-depth analysis of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets.

The study provides analysis of key market dynamics, which influence the adoption of CINV drugs

The report provides a quantitative analysis for the period of 2014–2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry.

Extensive analysis of the global market helps understand cancer inducing Nausea and vomiting drugs developed and marketed by the key companies.

Competitive intelligence of market players highlights the business practices and trends across various regions.

KEY MARKET SEGMENTS:

Patient Pool Type

Aloxi, Kytril

Emend

Netupitant-Palonosetron

Others

By Geography

North America

US

Canada

Mexico

Europe

Germany

France

UK

Rest of Europe

Asia-Pacific

China

Japan

Rest of Asia-Pacific

LAMEA

Latin America

Middle East

Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

GlaxoSmithKline plc

Helsinn Holding S.A.

Heron Therapeutics, Inc.

Merck & Co., Inc.

Tesaro, Inc

Contents

CHAPTER: 1 INTRODUCTION

- 1.1 Report Description
- 1.2 Key Benefits
- 1.3 Key Market Segments
- 1.4 Research Methodology
 - 1.4.1 Secondary Research
 - 1.4.2 Primary Research
 - 1.4.3 Analyst Tools and Models

CHAPTER: 2 EXECUTIVE SUMMARY

- 2.1 CXO Perspective

CHAPTER: 3 MARKET OVERVIEW

- 3.1 Market Definition and Scope
- 3.2 Key Findings
 - 3.2.1 Top Impacting Factors
 - 3.2.2 Top Investment Pockets
- 3.3 Porters Five Force Analysis
- 3.4 Drivers
 - 3.4.1 Growing Number of patients undergoing Chemotherapy
 - 3.4.2 Growing research and development efforts in order to discover a universal antiemetic therapy
 - 3.4.3 Introduction of novel delivery methods to improve patient compliance.
 - 3.4.4 Advancements in technology to discover new potential drug targets
- 3.5 Restraints
 - 3.5.1 Increasing side effects of CINV drugs
 - 3.5.2 High cost associated with the new drug discovery and in developing regions.
- 3.6 Opportunities
 - 3.6.1 Efficacy of combination therapy is expected to improve.
 - 3.6.2 Improved quality of life for patients with cancer.
- 3.7 Market Trends

CHAPTER: 4 CINV MARKET BY PATIENT POOL

- 4.1 Overview
- 4.2 Netupitant-Palonosetron FDC
 - 4.2.1 Key market trends
 - 4.2.2 Key growth factors & opportunities
 - 4.2.3 Market size & forecasts
- 4.3 Aloxi (palonosetron)
 - 4.3.1 Key market trends
 - 4.3.2 Key growth factors & opportunities
 - 4.3.3 Market size & forecasts
- 4.4 Kytril Generic (Granisetron)
 - 4.4.1 Key market trends
 - 4.4.2 Key growth factors & opportunities
 - 4.4.3 Market size & forecasts
- 4.5 Emend (aprepitant)
 - 4.5.1 Key market trends
 - 4.5.2 Key growth factors & opportunities
 - 4.5.3 Market size & forecasts

CHAPTER: 5 CINV MARKET BY GEOGRAPHY

- 5.1 North America
 - 5.1.1 Key Market Trends
 - 5.1.2 Key Growth Factors and Opportunities
 - 5.1.3 Market Size and Forecast
- 5.2 Europe
 - 5.2.1 Key Market Trends
 - 5.2.2 Key Growth Factors and Opportunities
 - 5.2.3 Market Size and Forecast
- 5.3 Asia-Pacific
 - 5.3.1 Key Market Trends
 - 5.3.2 Key Growth Factors and Opportunities
 - 5.3.3 Market Size and Forecast
- 5.4 Latin America, Middle East and Africa (LAMEA)
 - 5.4.1 Key Market Trends
 - 5.4.2 Key Growth Factors and Opportunities
 - 5.4.3 Market Size and Forecast

CHAPTER: 6 COMPANY PROFILES

- 6.1 Helsinn Holding S.A.
 - 6.1.1 Company Overview
 - 6.1.2 Key Strategies and Developments
 - 6.1.3 SWOT Analysis
- 6.2 Heron Therapeutics, Inc.
 - 6.2.1 Company Overview
 - 6.2.2 Business Performance
 - 6.2.3 Key Strategies and Developments
 - 6.2.4 SWOT Analysis
- 6.3 Merck & Co., Inc
 - 6.3.1 Company Overview
 - 6.3.2 Business Performance
 - 6.3.3 Key Strategies and Developments
 - 6.3.4 SWOT Analysis
- 6.4 GlaxoSmithKline plc
 - 6.4.1 Company Overview
 - 6.4.2 Business Performance
 - 6.4.3 Key Strategies and Developments
 - 6.4.4 Key Strategies and Developments
 - 6.4.5 SWOT Analysis
- 6.5 Cadila Pharmaceuticals Limited
 - 6.5.1 Company Overview
 - 6.5.2 Business Performance
 - 6.5.3 Key Strategies and Developments
 - 6.5.4 Key Strategies and Developments
 - 6.5.5 SWOT Analysis
- 6.6 Amneal Pharmaceuticals
 - 6.6.1 Company Overview
 - 6.6.2 Business Performance
 - 6.6.3 Key Strategies and Developments
 - 6.6.4 Key Strategies and Developments
 - 6.6.5 SWOT Analysis
- 6.7 Kyowa Kirin, Inc.
 - 6.7.1 Company Overview
 - 6.7.2 Business Performance
 - 6.7.3 Key Strategies and Developments
 - 6.7.4 Key Strategies and Developments
 - 6.7.5 SWOT Analysis
- 6.8 Acacia Pharma

- 6.8.1 Company Overview
 - 6.8.2 Business Performance
 - 6.8.3 Key Strategies and Developments
 - 6.8.4 Key Strategies and Developments
 - 6.8.5 SWOT Analysis
 - 6.9 Insys Therapeutics, Inc
 - 6.9.1 Company Overview
 - 6.9.2 Business Performance
 - 6.9.3 Key Strategies and Developments
 - 6.9.4 Key Strategies and Developments
 - 6.9.5 SWOT Analysis
 - 6.10 Tesaro, Inc.
 - 6.10.1 Company Overview
 - 6.10.2 Business Performance
 - 6.10.3 Key Strategies and Developments
 - 6.10.4 Key Strategies and Developments
 - 6.10.5 SWOT Analysis
- Details on financial performance, strategic moves and developments and SWOT analysis may not be captured for unlisted companies.

List Of Tables

LIST OF TABLES

TABLE 1 WORLD CINV MARKET BY PATIENT POOL(NETUPITANT-PALONOSETRON FDC) MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 2 WORLD CINV MARKET BY PATIENT POOL(ALOXI), (\$MILLION), GROWTH (%)2014-2022

TABLE 3 WORLD CINV MARKET BY PATIENT POOL(KYTRIL GENERIC), (\$MILLION), GROWTH (%)2014-2022

TABLE 4 WORLD CINV MARKET BY PATIENT POOL(EMEND), (\$MILLION), GROWTH (%)2014-2022

TABLE 5 NORTH AMERICA CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 6 EUROPE CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 7 ASIA CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 8 LAMEA CINV MARKET, (\$MILLION), GROWTH (%)2014-2022

TABLE 9 HELSINN HOLDING S.A.COMPANY SNAPSHOT

TABLE 9 HELSINN HOLDING S.A.OPERATING SEGMENTS

TABLE 10 HERON THERAPEUTICS, INC. COMPANY SNAPSHOT

TABLE 11 HERON THERAPEUTICS, INC.OPERATING SEGMENTS

TABLE 12 MERCK & CO., INC. COMPANY SNAPSHOT

TABLE 13 MERCK & CO., INC.OPERATING SEGMENTS

TABLE 14 GLAXOSMITHKLINE PLC COMPANY SNAPSHOT

TABLE 15 GLAXOSMITHKLINE PLC OPERATING SEGMENTS

TABLE 16 CADILA PHARMACEUTICALS LIMITED COMPANY SNAPSHOT

TABLE 17 CADILA PHARMACEUTICALS LIMITED OPERATING SEGMENTS

TABLE 18 AMNEAL PHARMACEUTICALS COMPANY SNAPSHOT

TABLE 19 AMNEAL PHARMACEUTICALS OPERATING SEGMENTS

TABLE 20 KYOWA KIRIN, INC. COMPANY SNAPSHOT

TABLE 21 KYOWA KIRIN, INC. OPERATING SEGMENTS

TABLE 22 ACACIA PHARMA COMPANY SNAPSHOT

TABLE 23 ACACIA PHARMA OPERATING SEGMENTS

TABLE 24 INSYS THERAPEUTICS, INC. COMPANY SNAPSHOT

TABLE 25 INSYS THERAPEUTICS, INC. OPERATING SEGMENTS

TABLE 26 TESARO, INC. COMPANY SNAPSHOT

TABLE 27 TESARO, INC. OPERATING SEGMENTS

List Of Figures

LIST OF FIGURES

FIG. 1 TOP IMPACTING FACTORS

FIG. 2 TOP INVESTMENT POCKETS

FIG. 3 PORTERS FIVE FORCES ANALYSIS OF LITHIUM-ION BATTERY MARKET

FIG. 4 WORLD CINV MARKET BY TYPE, 2015(PIE CHART OF GLOBAL NUMBERS BY TYPE)

FIG. 5 WORLD CINV MARKET BY GEOGRAPHY, 2015(PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY)

FIG. 6 NET SALES OF HERON THERAPEUTICS, INC., 2013-2015 (\$MILLION)

FIG. 7 NET SALES OF HERON THERAPEUTICS, INC., BY SEGMENT (%), 2015

FIG. 8 NET SALES OF HERON THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015

FIG. 10 NET SALES OF MERCK & CO., INC, 2013-2015 (\$MILLION)

FIG. 11 NET SALES OF MERCK & CO., INC., BY GEOGRAPHY (%), 2015

FIG. 11 NET SALES OF MERCK & CO., INC., BY SEGMENT (%), 2015

FIG. 12 NET SALES OF GLAXOSMITHKLINE PLC., 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF GLAXOSMITHKLINE PLC, BY SEGMENT (%), 2015

FIG. 14 NET SALES OF GLAXOSMITHKLINE PLC, BY GEOGRAPHY (%), 2015

FIG. 18 NET SALES OF KYOWA KIRIN, INC., 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF KYOWA KIRIN, INC., BY SEGMENT (%), 2015

FIG. 14 NET SALES OF KYOWA KIRIN, INC., BY GEOGRAPHY (%), 2015

FIG. 22 REVENUE OF INSYS THERAPEUTICS, INC., 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF INSYS THERAPEUTICS, INC., BY SEGMENT (%), 2015

FIG. 14 NET SALES OF INSYS THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015

FIG. 22 REVENUE OF TESARO, INC, 2013-2015 (\$MILLION)

FIG. 13 NET SALES OF TESARO, INC, BY SEGMENT (%), 2015

FIG. 14 NET SALES OF TESARO, INC, BY GEOGRAPHY (%), 2015

I would like to order

Product name: Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron) - Global Opportunities and Forecast 2014-2022

Product link: <https://marketpublishers.com/r/G2460A85F3EEN.html>

Price: US\$ 5,540.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2460A85F3EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970